Head-to-head evidence

BCMA CAR-NK (Hrain) vs Pamlectabart tismanitin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

💬 Discuss in AI Terminal →

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

BCMA CAR-NK (Hrain)

Developed by Hrain Biotechnology Co., Ltd.

Phase 1/2 in Multiple Myelomacell therapy (allogeneic BCMA-targeted CAR-NK)

Weak signal

NCT05008536 · Phase 1 · status unknown

This was an open-label, single-arm study with no randomization, no blinding, and no comparator arm, in only 27 participants. Results have not been posted yet. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

Unlock with Research ↗

Pamlectabart tismanitin

Developed by Heidelberg Pharma AG

Phase 1/2 in Multiple MyelomaADC (anti-BCMA antibody-targeted amanitin conjugate)

not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2028 · NCT04879043 (registry estimate)

Unlock with Research ↗

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCMA CAR-NK (Hrain)'s landscape · Pamlectabart tismanitin's landscape